Nath Bio-Genes

- There is no mention of any current or future fundraising through debt or equity in the transcript. - The company continues to maintain a strong balance sheet with a long-term zero debt status. - No plans for raising debt or equity were discussed during the conference call. - The management emphasized steady organic growth and improving financial performance without external capital infusion.

- The transcript does not explicitly mention any current or future capex, capital investment, or strategic investment details. - However, strategic emphasis is on diversification away from cotton and paddy towards non-cotton and non-paddy segments, which is yielding volume growth. - Expansion in the Win-Chi-Win product vertical with dedicated teams indicates investment in marketing and sales infrastructure. - Introduction and large-scale seed production of new hybrids in maize and paddy reflect capital allocation towards R&D and production capacity. - Appointment of a crop manager for rice suggests investment in market research and product development. - Efforts to fast-track international registrations (e.g., Sudan cotton hybrids) imply strategic investments in global market expansion. - No specific monetary figures or timelines for capex or investments are disclosed in this transcript.

- Nath Bio-Genes plans to maintain overall revenue growth of around 20% for the next year (FY22). - Cotton segment growth expected around 15%, down from 25-26% this year, as cotton prices are fixed and stable. - Significant growth anticipated in non-cotton segments: vegetables, paddy, bajra, maize, mustard, wheat, and rabi crops, some growing 25%-50%. - Focus on diversification away from cotton and paddy, with non-cotton and non-paddy portfolio showing strong volume growth. - Expansion in Win-Chi-Win product segment showing 60%-70% growth, with geographic spread increasing. - Introduction of new hybrids in rice and maize markets expected to drive volume increases and revenue growth. - Export opportunities expanding, especially with BT cotton hybrid registration in Sudan upcoming. - Working capital cycle improving, supporting growth plans. - Overall outlook is positive, with management confident of meeting growth guidance.

- The company aims for overall revenue growth of around 18% to 20% for FY21 despite COVID-19 disruptions. - Cotton segment growth is expected to be around 15% next year, with other crops like vegetables and non-cotton segments growing at higher rates (25%-50%). - Win-Chi-Win segment has shown strong growth (around 60%-70%) and is expected to continue expanding with increased focus and dedicated teams. - The gross margin is maintained around 52%-54%, indicating strong profitability. - Profit after tax grew by 13% to 49 crores in 9 months FY21, nearing last year’s profit with a quarter remaining. - EPS and intrinsic value of shares are gradually increasing due to rising profits and stable equity. - The company is confident about maintaining or improving margins amid growth due to product quality and higher volumes. - Working capital cycle is improving, which will support better financial health going forward.

- The transcript does not explicitly mention the current or expected order book or pending orders for Nath Bio-Genes (India) Limited. - However, it indicates a positive outlook with plans to maintain around 20% growth overall in the next financial year. - The company is gearing up well for the upcoming kharif season with sufficient production lined up. - Win-Chi-Win product supply is stable without significant container shortages despite some minor trade issues. - The company is increasing territories for Win-Chi-Win sales from 100 to around 175+. - Seed production for new hybrids in maize and paddy is underway to support volume growth. - Export registrations, particularly in Sudan, are being fast-tracked, indicating growth opportunities. - Management expresses confidence in meeting revenue guidance and improving working capital cycles.